Roche’s Atezolizumab Filing In Sight, With Pivotal Lung Cancer Data In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s atezolizumab meets primary endpoint in large Phase II pivotal BIRCH lung cancer study of PD-L1-positive patients, giving hope for an earlier filing of the PD-L1 inhibitor in 2015.